ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Mayo Clinic
Sun Yat-sen University
Rutgers, The State University of New Jersey
Sichuan Enray Pharmaceutical Sciences Company
Grey Wolf Therapeutics
Washington University School of Medicine
University of Arizona
Institut Curie
Centre Leon Berard
Cancer Research UK
University of California, Irvine
Cancer Research UK
Stanford University
Tianjin Medical University Cancer Institute and Hospital
UNICANCER
Peking Union Medical College Hospital
Peking Union Medical College Hospital
Baylor College of Medicine
Cancer Research UK
Second Affiliated Hospital of Guangzhou Medical University
University Medical Center Groningen
University of Southampton
Dana-Farber Cancer Institute
University Health Network, Toronto
Imperial College London
Peking University Third Hospital
Peking Union Medical College Hospital
Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-Immune Medical Institute
Fuda Cancer Hospital, Guangzhou
Barts & The London NHS Trust
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Southern California
University of Miami
Fuda Cancer Hospital, Guangzhou
University Health Network, Toronto
University Health Network, Toronto
University Health Network, Toronto
All India Institute of Medical Sciences
ARCAGY/ GINECO GROUP
Korea Cancer Center Hospital
AGO Study Group
University of Plymouth
Sheffield Teaching Hospitals NHS Foundation Trust
Julius-Maximilians University